Eli Lilly director receives stock award grant
Eli Lilly & Co director Juan R. Luciano received a stock-based compensation award rather than cash fees.
Rhea-AI Filing Summary
Eli Lilly & Co director Juan R. Luciano received a stock-based compensation award rather than cash fees. On 2026-03-16, he acquired 16.092 shares of common stock at $989.12 per share as a grant or award. Following this transaction, he directly holds 16,817.420 shares of Eli Lilly common stock.
According to the company’s directors’ deferral plan, these shares have been deferred as stock units in lieu of cash compensation and will be settled in actual shares of common stock after Luciano separates from service as a director.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 16.092 | $989.12 | $16K |
Footnotes (1)
- F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Eli Lilly (LLY) director Juan R. Luciano report on this Form 4?
Was the Eli Lilly (LLY) Form 4 transaction a market purchase or sale?
Does the Eli Lilly (LLY) Form 4 indicate any tax-withholding or derivative exercises?
AI-generated analysis. How Rhea-AI works. Not financial advice.